MX2012001346A - Polipeptidos del factor ix modificados y usos de los mismos. - Google Patents

Polipeptidos del factor ix modificados y usos de los mismos.

Info

Publication number
MX2012001346A
MX2012001346A MX2012001346A MX2012001346A MX2012001346A MX 2012001346 A MX2012001346 A MX 2012001346A MX 2012001346 A MX2012001346 A MX 2012001346A MX 2012001346 A MX2012001346 A MX 2012001346A MX 2012001346 A MX2012001346 A MX 2012001346A
Authority
MX
Mexico
Prior art keywords
polypeptides
modified factor
factor
methods
relates
Prior art date
Application number
MX2012001346A
Other languages
English (en)
Inventor
Alan Brooks
Jun Wang
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Heiner Apeler
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012001346(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2012001346A publication Critical patent/MX2012001346A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a polipéptidos del Factor IX modificados tales como polipéptidos del Factor IX con una o más sustituciones de aminoácidos. La invención también se refiere a procedimientos para fabricar polipéptidos del Factor IX modificados y a procedimientos para el uso de polipéptidos del Factor IX modificados, para tratar, por ejemplo, pacientes afectados de hemofilia B.
MX2012001346A 2009-07-31 2010-08-02 Polipeptidos del factor ix modificados y usos de los mismos. MX2012001346A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2012001346A true MX2012001346A (es) 2012-02-17

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001346A MX2012001346A (es) 2009-07-31 2010-08-02 Polipeptidos del factor ix modificados y usos de los mismos.

Country Status (21)

Country Link
US (1) US20120164130A1 (es)
EP (1) EP2461821A4 (es)
JP (1) JP2013500726A (es)
KR (1) KR20120060209A (es)
CN (1) CN102573890A (es)
AU (1) AU2010278721A1 (es)
BR (1) BR112012002072A2 (es)
CA (1) CA2769258A1 (es)
CL (1) CL2012000238A1 (es)
CR (1) CR20120052A (es)
CU (3) CU20120018A7 (es)
DO (1) DOP2012000030A (es)
EA (1) EA201290069A1 (es)
EC (1) ECSP12011637A (es)
GT (1) GT201200023A (es)
IN (1) IN2012DN00908A (es)
MX (1) MX2012001346A (es)
PE (1) PE20121643A1 (es)
SG (1) SG178119A1 (es)
WO (1) WO2011014890A1 (es)
ZA (1) ZA201200716B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
PL3581650T3 (pl) 2008-09-15 2023-05-22 Uniqure Biopharma B.V. Zmutowany polipeptyd czynnika ix, jego zastosowania i sposób jego wytwarzania
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2769326A1 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2533619C2 (ru) 2009-07-27 2014-11-20 Лайпоксен Текнолоджиз Лимитед Гликополисиалирование белков, не являющихся белками свертывания крови
EP2598172B1 (en) * 2010-07-30 2019-03-27 Baxalta GmbH Nucleophilic catalysts for oxime linkage
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
PT2794665T (pt) * 2011-12-19 2018-01-24 Dilafor Ab Glicosaminoglicanos não anticoagulativos que compreendem unidade repetitiva de dissacáridos e sua utilização médica
EP2922871B1 (en) * 2012-11-20 2019-06-19 The University of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
DK2970424T3 (en) * 2013-03-13 2017-07-31 Lilly Co Eli Modified leptide polypeptides in dogs
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
WO2018022844A2 (en) * 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086091A2 (en) * 2001-04-25 2002-10-31 The Regents Of The University Of California Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005055950A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
US20120164130A1 (en) 2012-06-28
WO2011014890A1 (en) 2011-02-03
CR20120052A (es) 2012-06-04
KR20120060209A (ko) 2012-06-11
DOP2012000030A (es) 2012-02-29
EP2461821A4 (en) 2013-07-03
ECSP12011637A (es) 2012-02-29
BR112012002072A2 (pt) 2016-11-08
CU20120018A7 (es) 2012-06-21
CU20130057A7 (es) 2013-06-28
PE20121643A1 (es) 2012-11-25
ZA201200716B (en) 2013-07-31
JP2013500726A (ja) 2013-01-10
EA201290069A1 (ru) 2012-07-30
GT201200023A (es) 2014-01-27
AU2010278721A1 (en) 2012-02-16
CA2769258A1 (en) 2011-02-03
IN2012DN00908A (es) 2015-04-03
CU20130058A7 (es) 2013-06-28
EP2461821A1 (en) 2012-06-13
SG178119A1 (en) 2012-03-29
CL2012000238A1 (es) 2012-10-05
CN102573890A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
MX338884B (es) Composiciones y metodos que comprenden variantes de proteasa.
MY192475A (en) Modified factor ix polypeptides and uses thereof
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MX2011007930A (es) Conjugados de insulina cristalina.
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
GEP20146056B (en) Acylated glucagon analogues
TN2012000302A1 (en) Oxyntomodulin peptide analogue
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
IN2012DN03883A (es)
WO2009137254A3 (en) Modified factor ix polypeptides and uses thereof
MX2021001494A (es) Anticuerpos dkk1 y metodos de uso.
MX2019001095A (es) Proteinas de dominio de armazon basadas en fibronectina que se unen a la proteina convertasa subtilisina kexina tipo q (pcsk9).
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
MX2010010457A (es) Vectores recombinantes de rinovirus.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
PH12014502876A1 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
MX2011008179A (es) Peptidos para vacuna.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
MY180681A (en) Compositions and methods for treatment of aortic fibrosis
MX2011010046A (es) Derivados de diaminopteridina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal